JP2013501814A5 - - Google Patents

Download PDF

Info

Publication number
JP2013501814A5
JP2013501814A5 JP2012524903A JP2012524903A JP2013501814A5 JP 2013501814 A5 JP2013501814 A5 JP 2013501814A5 JP 2012524903 A JP2012524903 A JP 2012524903A JP 2012524903 A JP2012524903 A JP 2012524903A JP 2013501814 A5 JP2013501814 A5 JP 2013501814A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
h7cr
interaction
activity
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012524903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501814A (ja
JP5883384B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/045479 external-priority patent/WO2011020024A2/en
Publication of JP2013501814A publication Critical patent/JP2013501814A/ja
Publication of JP2013501814A5 publication Critical patent/JP2013501814A5/ja
Application granted granted Critical
Publication of JP5883384B2 publication Critical patent/JP5883384B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012524903A 2009-08-13 2010-08-13 免疫機能を調節する方法 Expired - Fee Related JP5883384B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23365009P 2009-08-13 2009-08-13
US61/233,650 2009-08-13
US28995109P 2009-12-23 2009-12-23
US61/289,951 2009-12-23
PCT/US2010/045479 WO2011020024A2 (en) 2009-08-13 2010-08-13 Methods of modulating immune function

Publications (3)

Publication Number Publication Date
JP2013501814A JP2013501814A (ja) 2013-01-17
JP2013501814A5 true JP2013501814A5 (enExample) 2013-10-03
JP5883384B2 JP5883384B2 (ja) 2016-03-15

Family

ID=43297014

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012524903A Expired - Fee Related JP5883384B2 (ja) 2009-08-13 2010-08-13 免疫機能を調節する方法

Country Status (7)

Country Link
US (3) US8840889B2 (enExample)
EP (2) EP2464661B1 (enExample)
JP (1) JP5883384B2 (enExample)
AU (2) AU2010282340B2 (enExample)
CA (1) CA2769822C (enExample)
ES (1) ES2666152T3 (enExample)
WO (1) WO2011020024A2 (enExample)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100266495A1 (en) * 2004-05-21 2010-10-21 Brigham Young University Anti-Cancer Activity of an Anti-Thymidine Kinase Monoclonal Antibody
US7520860B2 (en) 2005-04-13 2009-04-21 Marie G. Johnson Detection of coronary artery disease using an electronic stethoscope
ES2537580T3 (es) 2007-09-04 2015-06-09 Compugen Ltd. Polipéptidos y polinucleótidos, y usos de los mismos como una diana farmacológica para producir fármacos y agentes biológicos
JP5883384B2 (ja) * 2009-08-13 2016-03-15 ザ ジョンズ ホプキンス ユニバーシティー 免疫機能を調節する方法
WO2011146313A1 (en) 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
EP2726503B1 (en) 2011-06-30 2019-09-04 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
BR112014007788A2 (pt) 2011-10-03 2017-04-18 Univ North Carolina Chapel Hill compostos de pirrolopirimidina para tratamento do câncer
KR20140126357A (ko) 2012-02-01 2014-10-30 컴퓨젠 엘티디. C1orf32 항체 및 이의 암 치료를 위한 용도
WO2013148147A1 (en) 2012-03-26 2013-10-03 The U.S.A., As Represented By The Secretary Dept. Of Health And Human Services Dna methylation analysis for the diagnosis, prognosis and treatment of adrenal neoplasms
MX2014013632A (es) 2012-05-22 2015-02-05 Univ North Carolina Compuestos de pirimidina para el tratamiento de cancer.
TWI556194B (zh) * 2012-06-29 2016-11-01 希科母股份有限公司 對象檢出裝置、對象檢出方法及對象檢出用電腦程式
US9562047B2 (en) 2012-10-17 2017-02-07 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
WO2014085225A1 (en) 2012-11-27 2014-06-05 The University Of North Carolina At Chapel Hill Pyrimidine compounds for the treatment of cancer
MX2015008117A (es) 2012-12-21 2016-03-31 Amplimmune Inc Anticuerpos anti-h7cr.
US20140205609A1 (en) * 2013-01-24 2014-07-24 Fred T. Valentine Methods for inducing systemic immune responses to cancer
US10093737B2 (en) 2013-03-01 2018-10-09 Albert Einstein College Of Medicine, Inc. HHLA2 as a novel inhibitor of human immune system and uses thereof
JP2016519108A (ja) 2013-04-18 2016-06-30 アルモ・バイオサイエンシーズ・インコーポレイテッド インターロイキン−10を疾病及び疾患の治療に用いる方法
JP6682426B2 (ja) * 2013-05-24 2020-04-15 メディミューン,エルエルシー 抗b7−h5抗体およびその使用
CN105848674A (zh) * 2013-11-11 2016-08-10 阿尔莫生物科技股份有限公司 将白细胞介素-10用于治疗疾病和病症的方法
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9603850B2 (en) 2014-04-11 2017-03-28 The University Of North Carolina At Chapel Hill MerTK-specific pyrazolopyrimidine compounds
WO2015167948A1 (en) * 2014-04-30 2015-11-05 Albert Einstein College Of Medicine Of Yeshiva University Tmigd2 and its derivatives as blockers or binders of cancer-expressed hhla2 for immunotherapies
SMT202100116T1 (it) 2014-05-28 2021-05-07 Agenus Inc Anticorpi anti-gitr e metodi di utilizzo degli stessi
AU2015271126A1 (en) * 2014-06-04 2016-12-08 Ngm Biopharmaceuticals, Inc. Compositions and methods for targeting a pathway
WO2016109546A2 (en) 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
SG11201705844SA (en) * 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
RS60614B1 (sr) * 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
SG10202103445QA (en) * 2015-04-13 2021-05-28 Regeneron Pharma Humanized sirpa-il15 knockin mice and methods of use thereof
EP3283508B1 (en) 2015-04-17 2021-03-17 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
ITUB20151014A1 (it) * 2015-05-27 2016-11-27 Univ Degli Studi Del Piemonte Orientale Amedeo Avogadro Ligandi del recettore b7h nel trattamento di osteopenia e osteoporosi
CN107849144B (zh) 2015-05-29 2021-09-17 艾吉纳斯公司 抗-ctla-4抗体及其使用方法
US10968277B2 (en) 2015-10-22 2021-04-06 Jounce Therapeutics, Inc. Gene signatures for determining ICOS expression
EP3383430A4 (en) 2015-12-02 2019-12-18 Agenus Inc. ANTIBODIES AND METHOD FOR USE THEREOF
US11547739B2 (en) * 2015-12-16 2023-01-10 La Jolla Institute For Allergy And Immunology Peptides and methods related to ICOS signaling
US10709708B2 (en) 2016-03-17 2020-07-14 The University Of North Carolina At Chapel Hill Method of treating cancer with a combination of MER tyrosine kinase inhibitor and an epidermal growth factor receptor (EGFR) inhibitor
KR102824067B1 (ko) 2016-04-15 2025-06-23 알파인 이뮨 사이언시즈, 인코포레이티드 Icos 리간드 변이체 면역조절 단백질 및 그의 용도
EP3443000B1 (en) 2016-04-15 2025-11-12 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
BR112018076260A2 (pt) 2016-06-20 2019-03-26 Kymab Limited anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11834490B2 (en) 2016-07-28 2023-12-05 Alpine Immune Sciences, Inc. CD112 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
CN116640214A (zh) 2016-08-09 2023-08-25 科马布有限公司 分离抗体及其应用
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
CN106755372B (zh) * 2016-12-12 2020-03-31 青岛泱深生物医药有限公司 一种分子标志物在口腔鳞状细胞癌诊断和治疗中的应用
US11192933B2 (en) * 2017-02-27 2021-12-07 Shattuck Labs, Inc. VSIG8-based chimeric proteins
CN110809581A (zh) 2017-03-16 2020-02-18 高山免疫科学股份有限公司 Pd-l2变体免疫调节蛋白及其用途
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US10752689B2 (en) * 2017-06-26 2020-08-25 Bio-Techne Corporation Hybridoma clones, monoclonal antibodies to VSIG-4, and methods of making and using
UA128472C2 (uk) 2017-08-25 2024-07-24 Файв Прайм Терапеутікс Інк. B7-h4 антитіла і методи їх використання
KR102813968B1 (ko) 2017-10-10 2025-05-29 알파인 이뮨 사이언시즈, 인코포레이티드 Ctla-4 변이체 면역조절 단백질 및 이의 용도
MX2020004540A (es) * 2017-10-18 2020-08-03 Alpine Immune Sciences Inc Proteinas inmunomoduladoras de ligando icos variante y composiciones y metodos relacionados.
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3735417A1 (en) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
JP7054955B2 (ja) * 2018-01-12 2022-04-15 ゲノム アンド カンパニー Kirrel2及びkirrel2抑制剤の新規用途
BR112020016986A2 (pt) 2018-02-21 2021-03-02 Five Prime Therapeutics, Inc. formulações de anticorpo contra b7-h4
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
BR112020015999A2 (pt) * 2018-04-06 2020-12-15 Dana-Farber Cancer Institute, Inc. Kir3dl3 como um receptor de hhla2, anticorpos anti-hhla2 e usos dos mesmos
CN108872588B (zh) * 2018-06-14 2021-05-28 华南农业大学 一种与种公猪繁殖性能密切相关的精子蛋白标记spaca4及其应用
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
JP2021533796A (ja) * 2018-08-21 2021-12-09 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド B7−h7結合剤及びその使用方法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP2022527761A (ja) * 2019-03-26 2022-06-06 フォーティ セブン, インコーポレイテッド がん治療のための多重特異性作用物質
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
WO2022243378A1 (en) 2021-05-18 2022-11-24 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
CN119040454A (zh) * 2024-09-27 2024-11-29 华南农业大学 Slc26a2基因作为肉鸡胫骨软骨发育不良标志物的应用

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5190929A (en) 1988-05-25 1993-03-02 Research Corporation Technologies, Inc. Cyclophosphamide analogs useful as anti-tumor agents
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
AU643109B2 (en) 1990-12-14 1993-11-04 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DK0606217T4 (da) * 1991-06-27 2009-03-30 Bristol Myers Squibb Co CTL4-receptor, fusionsproteiner indeholdende den samt anvendelse deraf
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6162432A (en) 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
DE4135070C1 (enExample) 1991-10-24 1993-05-19 Institut Fuer Rundfunktechnik Gmbh, 8000 Muenchen, De
DE69233204T2 (de) 1991-12-13 2004-07-15 Xoma Corp., Berkeley Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5532159A (en) 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
AU3382595A (en) 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
ATE238668T1 (de) 1995-01-17 2003-05-15 Brigham & Womens Hospital Rezeptorspezifischer transepithelialer transport von immunogenen
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO1998023289A1 (en) 1996-11-27 1998-06-04 The General Hospital Corporation MODULATION OF IgG BINDING TO FcRn
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US7411051B2 (en) * 1997-03-07 2008-08-12 Human Genome Sciences, Inc. Antibodies to HDPPA04 polypeptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DK1490386T3 (da) 1998-03-10 2008-12-15 Genentech Inc Nyt polypeptid og nukleinsyrer kodende for dette
AU4640600A (en) 1999-05-11 2000-11-21 Eli Lilly And Company Amyloid precursor protein protease and related nucleic acid compounds
EP1514933A1 (en) 1999-07-08 2005-03-16 Research Association for Biotechnology Secretory protein or membrane protein
EP1210428B1 (en) 1999-08-23 2015-03-18 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US6429303B1 (en) 1999-09-03 2002-08-06 Curagen Corporation Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
EP1212344A4 (en) 1999-09-03 2004-08-04 Human Genome Sciences Inc POLYNUCLEOTIDES, POLYPEPTIDES AND ANTIBODIES OF THE TYPE B7
ATE366814T1 (de) * 1999-09-21 2007-08-15 Genetics Inst Llc Gl50 moleküle, sowie verwendungen derselben
EP2341074A1 (en) 2000-03-01 2011-07-06 MedImmune, LLC Antibodies binding to the f protein of a respiratory syncytial virus (rsv)
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
US6416999B1 (en) 2000-04-07 2002-07-09 Raven Biotechnologies, Inc. Human Müllerian duct-derived epithelial cells and methods of isolation and uses thereof
US6987024B1 (en) 2000-04-10 2006-01-17 Raven Biotechnologies, Inc. Human ovarian mesothelial cells and methods of isolation and uses thereof
US6436704B1 (en) 2000-04-10 2002-08-20 Raven Biotechnologies, Inc. Human pancreatic epithelial progenitor cells and methods of isolation and use thereof
CA2405550A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US20060154313A1 (en) 2000-04-13 2006-07-13 Immunex Corporation Human B7 polypeptide B7-H3A
JP3597140B2 (ja) * 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
AU2001264747A1 (en) 2000-05-22 2001-12-03 Idec Pharmaceuticals Corporation Identification of unique binding interactions between certain antibodies and thehuman b7.1 and b7.2 co-stimulatory antigens
EP1892251A3 (en) 2000-06-06 2008-12-31 Brystol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
US6965018B2 (en) 2000-06-06 2005-11-15 Bristol-Myers Squibb Company Antibodies directed to B7-related polypeptide, BSL-2
AU7298201A (en) * 2000-06-23 2002-01-08 Biogen Inc Gp286 nucleic acids and polypeptides
EP1301524A1 (en) * 2000-06-30 2003-04-16 Human Genome Sciences, Inc. B7-like polynucleotides, polypeptides, and antibodies
US6635750B1 (en) 2000-07-20 2003-10-21 Millennium Pharmaceuticals, Inc. B7-H2 nucleic acids, members of the B7 family
WO2002010187A1 (en) 2000-07-27 2002-02-07 Mayo Foundation For Medical Education And Research B7-h3 and b7-h4, novel immunoregulatory molecules
EP1327638A4 (en) 2000-09-12 2004-09-29 Kirin Brewery NEW WALL MEMBRANE OF DENDRITIC CELLS AND THEIR USE
US20030134283A1 (en) 2000-10-03 2003-07-17 Peterson David P. Genes regulated in dendritic cell differentiation
WO2002032375A2 (en) 2000-10-18 2002-04-25 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8h9
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
RU2322500C2 (ru) 2000-12-01 2008-04-20 Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. Малые молекулы рнк, опосредующие интерференцию рнк
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US7651541B2 (en) 2001-01-10 2010-01-26 State Line Holdings, LLC Chemical change agent
AU2002250236A1 (en) 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
WO2002097046A2 (en) 2001-05-25 2002-12-05 Amgen, Inc. B7 related protein-2 molecules and uses thereof
US20070015144A9 (en) 2001-05-25 2007-01-18 Genset, S.A. Human cDNAs and proteins and uses thereof
AU2001286171B2 (en) 2001-05-25 2008-01-10 Serono Genetics Institute S.A. Human CDNAs and proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
AU2002347761A1 (en) 2001-08-02 2003-02-24 Eli Lilly And Company Novel polypeptide analogs and fusions and their methods of use
WO2003068938A2 (en) 2002-02-12 2003-08-21 Raven Biotechnologies, Inc Human fetal bladder-derived epithelial cells
US20040162236A1 (en) 2002-04-01 2004-08-19 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
EP1575509B1 (en) 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
CA2485373A1 (en) 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
EP1565489B1 (en) 2002-06-19 2010-11-17 Raven Biotechnologies, Inc. Internalizing antibodies specific for the RAAG10 cell surface target
EP1539218A4 (en) * 2002-06-20 2007-08-22 Univ California COMPOSITIONS AND METHODS FOR MODULATING LYMPHOCYTE ACTIVITY
US20060275287A1 (en) 2002-06-21 2006-12-07 Brad St Croix Scroll compressor
CA2494485A1 (en) 2002-07-25 2004-02-05 Medimmune, Inc. Methods of treating and preventing rsv, hmpv, and piv using anti-rsv, anti-hmpv, and anti-piv antibodies
DK2284266T3 (da) 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
AU2004280333A1 (en) 2003-08-22 2005-04-21 Medimmune, Llc Humanization of antibodies
JP2008518936A (ja) 2004-10-29 2008-06-05 メディミューン,インコーポレーテッド Rsv感染症および関連状態を予防および治療する方法
JP2008546426A (ja) * 2005-05-12 2008-12-25 ザイモジェネティクス, インコーポレイテッド T細胞を共刺激するためにpHHLA2を使用する方法
ATE552837T1 (de) 2005-12-02 2012-04-15 Univ Johns Hopkins Verwendung von hochdosierten oxazaphosphorin- arzneimitteln zur behandlung von immunstörungen
WO2007070488A2 (en) 2005-12-12 2007-06-21 The Cbr Institute For Biomedical Research, Inc. Integrin alpha l i domain mutants with increased binding affinity
CA2673659A1 (en) * 2006-12-27 2008-07-10 The Johns Hopkins University Methods of detecting and diagnosing inflamatory responses and disorders by determining the level of soluble b7-h4
US20100285039A1 (en) 2008-01-03 2010-11-11 The Johns Hopkins University B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells
JP5883384B2 (ja) * 2009-08-13 2016-03-15 ザ ジョンズ ホプキンス ユニバーシティー 免疫機能を調節する方法
MX2015008117A (es) * 2012-12-21 2016-03-31 Amplimmune Inc Anticuerpos anti-h7cr.

Similar Documents

Publication Publication Date Title
JP2013501814A5 (enExample)
EP4025257A4 (en) Antibody-drug conjugate comprising antibody against human ror1, and use for the same
UA109633C2 (uk) Антитіло людини проти тканинного фактора
NZ612175A (en) Anti ccr4 antibodies and uses thereof
JP2009286795A5 (enExample)
JP2014169326A5 (enExample)
CY1119852T1 (el) Σκευασμα αντισωματος και θεραπευτικα σχηματα
EA201400855A1 (ru) Моноклональные антитела человека, полученные из в-клеток человека и обладающие нейтрализующей активностью против вирусов гриппа а
JP2014530226A5 (enExample)
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
RU2011129204A (ru) Антитела против ангиопоэтина-2 человека
CY1111011T1 (el) Χρηση των anti-cd40 μονοκλωνικων αντισωματων για την θεραπευτικη αγωγη πολλαπλου μυελωματος
MY157564A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
JP2012021001A5 (enExample)
RU2013151455A (ru) Антитела и другие молекулы, которые связывают в7-н1 и pd-1
BR112012019098A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer e anticorpo
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
JP2009539841A5 (enExample)
EA033400B1 (ru) Антитело против cd3 и его применение
DE602007013618D1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
EP2535353A8 (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
JP2010500370A5 (enExample)
WO2013013025A3 (en) Anti-cxcr4 antibodies and methods of use
JP2013537539A5 (enExample)